- Correction
- Open access
- Published:
Correction: Dapaglifozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling
Cardiovascular Diabetology volume 21, Article number: 224 (2022)
The Original Article was published on 28 September 2022
Correction: Cardiovascular Diabetology (2022) 21:197 https://doi.org/10.1186/s12933-022-01614-5
Following publication of the original article [1], the author noticed the error in Fig. 6. In the published article, Figs. 4 and 6 look same. The author has wrongly uploaded Fig. 6 in the manuscript package which has been processed by the typesetter. However, the text citations and caption of Fig. 6 seems to be correct. Now this has been corrected with this erratum. The corrected Fig. 6 has been given in this correction.
Assessment of [Ca2+]SR by measurement of caffeine-induced CaTs. a Representative recording of caffeine-induced CaTs from a single RVCM for the 4 groups (caffeine = 10 mmol/L), which was used to estimate the total [Ca2+]SR content. b CaT amplitude. c CaT decay time constant. Each point represents the result from a single RVCM. RVCM right ventricular cardiomyocyte, CaT Ca2+ transient, [Ca2+]SR sarcoplasmic reticulum Ca2+ content. n/N = 15/5 = cells/rats per group. The horizontal lines show the mean ± SEM. One-way ANOVA or the nonparametric Wilcoxon signed-rank test. *p < 0.05, **p < 0.01, ***p < 0.001
Reference
Wu J, Liu T, Shi S, Fan Z, Hiram R, Xiong F, Cui B, Su X, Chang R, Zhang W, Yan M, Tang Y, Huang H, Wu G, Huang C. Dapaglifozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling. Cardiovasc Diabetol. 2022;21:197. https://doi.org/10.1186/s12933-022-01614-5.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Wu, J., Liu, T., Shi, S. et al. Correction: Dapaglifozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling. Cardiovasc Diabetol 21, 224 (2022). https://doi.org/10.1186/s12933-022-01669-4
Published:
DOI: https://doi.org/10.1186/s12933-022-01669-4